(NASDAQ: NUVL) Nuvalent's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.12%.
Nuvalent's earnings in 2025 is -$381,435,000.On average, 19 Wall Street analysts forecast NUVL's earnings for 2025 to be -$425,741,440, with the lowest NUVL earnings forecast at -$416,827,597, and the highest NUVL earnings forecast at -$427,515,484. On average, 19 Wall Street analysts forecast NUVL's earnings for 2026 to be -$428,417,047, with the lowest NUVL earnings forecast at -$457,441,568, and the highest NUVL earnings forecast at -$367,205,264.
In 2027, NUVL is forecast to generate -$314,740,099 in earnings, with the lowest earnings forecast at -$473,117,136 and the highest earnings forecast at -$202,306,434.